Standard Artesunate Dosage in Combination Therapy
Artesunate, used for severe malaria, starts with an intravenous loading dose of 2.4 mg/kg body weight on day 1, followed by 1.2 mg/kg at 12 and 24 hours, then 1.2 mg/kg daily for up to 7 days. It requires pairing with a full course of oral artemisinin-based combination therapy (ACT), such as artemether-lumefantrine or artesunate-amodiaquine, to clear residual parasites and prevent recrudescence.[1][2]
Adjustments for Weight and Age
Dosage scales by body weight bands:
- Infants <5 kg: 3 mg/kg loading dose, then 1.5 mg/kg.
- Children 5-8.9 kg: Fixed 20 mg vial per dose.
- Adults >60 kg: Use 120 mg vial per dose.
No routine adjustment for age alone, but lower weights in children trigger proportional reductions to avoid overdose.[1][3]
Adjustments for Renal or Hepatic Impairment
No specific dose changes needed for mild-to-moderate kidney or liver issues, as artesunate clears rapidly via metabolism to dihydroartemisinin. Monitor closely in severe cases; switch to oral ACT sooner if organ function stabilizes. Evidence from WHO guidelines shows no accumulation in impairment.[2][4]
Timing and Transition in Combinations
Give IV artesunate every 12 hours initially only if severe symptoms persist; otherwise, daily after loading. Transition to oral ACT once the patient can swallow (typically day 2-3), completing the partner's full 3-day regimen. Overlap by one dose if needed to ensure seamless coverage.[1][2]
Differences by Partner Drug
| Partner ACT | Artesunate IV Duration | Transition Notes |
|-------------|-------------------------|------------------|
| Artemether-lumefantrine | Up to 24 hours post-loading, then oral | Start oral 8 hours after last IV if tolerated. |
| Artesunate-amodiaquine | 24 hours minimum | Avoid if G6PD deficiency due to amodiaquine risk. |
| Dihydroartemisinin-piperaquine | Up to 7 days IV if severe | Piperaquine extends protection; monitor ECG. |
Choice depends on regional availability and resistance patterns.[2][5]
Special Cases: Pregnancy, Obesity, Recurrence